Cirrhosis of the liver
Conditions
Sponsors
Nanfang Hospital, Southern Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Obtain informed consent from subjects; 2. Age: 18-75; 3. Clinically definite diagnosis of cirrhosis; 4. Gastroscopy confirmed esophageal and gastric varicose bleeding (the time for the most recent bleeding to TIPS was more than 5 days); 5. Imaging examination suggested moderate and severe ascites; 6. Child-pugh score of liver function: 7-12
Exclusion criteria
Exclusion criteria: 1. Hepatocellular carcinoma or other intrahepatic and intrahepatic malignant tumors; 2. Poor etiology control of cirrhosis; 3. The TIPS of the common contraindications: congestive heart failure (NYHA classification > III or pulmonary hypertension, polycystic liver, etc. 4. Child-pugh score >13 or 60 mol/L of total bilirubin > (3.5 mg/dl), creatinine >180 mol/L(2.1 mg/dl). 5. Isolated gastric fundus or ectopic varicose vein bleeding; 6. Spontaneous dominant hepatic encephalopathy; 7. Previous or present portal vein thrombosis or buga syndrome; 8. Known coagulation disorders other than cirrhosis; 9. History of peptic ulcer, etc., in the past 6 months; 10. Unstable angina pectoris or myocardial infarction 6 months prior to random allocation; 11. Arrhythmias requiring antiarrhythmic treatment (beta blockers or digoxin may be used); 12. Uncontrolled hypertension (systolic > 150mm, or diastolic > 90mmHg, despite optimal treatment); 13. Have had a liver transplant or liver transplant candidate; 14. History of allotransplantation; 15. history of hemorrhagic stroke; 16. A history of major surgery or significant traumatic injury within 1 year prior to randomization; 17. Any complication that limits the patient's treatment or reduces his or her expectation of survival to less than 12 months; 18. Any disease or condition that is unstable or may endanger patient safety and compliance with the study; 19. Seizures requiring medication; 20. A known history of human immunodeficiency virus (HIV) infection; 21. Substance abuse, medical, psychological or social conditions that may affect the patient's participation in the study or the assessment of the study results; 22. Known allergy to research drugs; 23. Pregnancy or lactation; 24. Poor compliance; 25. Participate in another clinical study; 26. Have a close relationship with the research center, such as close relatives of the researcher, subordinate personnel (such as staff or students of the research center who have access to the research records and CRF data).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| varicose vein rebleeding rate; | — |
Countries
China
Contacts
Public ContactJianbo Zhao
Department of Interventional Therapy, Nanfang Hospital, Southern Medical University
Outcome results
None listed